Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator's Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies

NCT02083653 is registered in ClinicalTrials.gov with Symphogen A/S as lead sponsor.

NCT NCT02083653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02083653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator's Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies
Lead sponsor
Symphogen A/S
Phase
Phase 2
Overall status
Completed
Start date
March 6, 2014
Completion date
April 26, 2017
Enrollment
254 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer